Pharmaust Limited (AU:NUZ)
ASX:NUZ
Want to see AU:NUZ full AI Analyst Report?
Top Page
Pharmaust Limited
(Sydney:NUZ)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.07
â–Ľ(-35.00% Downside)
Action:Reiterated
Date:03/17/26
The score is primarily constrained by very weak financial performance (zero revenue, widening losses, accelerating cash burn, and rapid equity erosion). Technicals add further pressure due to a clear downtrend, while valuation is neutral-to-weak given the negative P/E and lack of dividend data.
Positive Factors
Low financial leverage
Zero reported debt materially lowers interest and refinancing obligations, giving management structural flexibility to prioritize R&D or strategic deals. For a cash-burning biotech, low leverage reduces solvency pressure and preserves optionality around timing and structure of future funding.
Negative Factors
Revenue collapsed to zero
Revenue dropping to zero after prior multi-year sales undermines the commercial engine and shifts the company to pure funding-dependent development. Over 2–6 months this materially increases reliance on external capital or partnerships to sustain programs and operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Zero reported debt materially lowers interest and refinancing obligations, giving management structural flexibility to prioritize R&D or strategic deals. For a cash-burning biotech, low leverage reduces solvency pressure and preserves optionality around timing and structure of future funding.
Read all positive factors
Pharmaust Limited (NUZ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$49.25M
Dividend YieldN/A
Average Volume (3M)1.10M
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS Growth5.16%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding746,274,100
10 Day Avg. Volume1,596,000
30 Day Avg. Volume1,096,098
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)25.24
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.28Price Target Upside180.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmaust Limited Business Overview & Revenue Model
Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate i...
How the Company Makes Money
null...
Pharmaust Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 857.35K | 0.00 | 0.00 | 2.82M | 3.38M | 3.38M |
| Gross Profit | 855.71K | 0.00 | -1.64K | -929.53K | -223.52K | 3.07M |
| EBITDA | -9.45M | -18.48M | -9.45M | -9.45M | -1.30M | -1.30M |
| Net Income | -7.69M | -16.59M | -9.03M | -9.03M | -1.71M | -1.71M |
Balance Sheet | ||||||
| Total Assets | 11.12M | 4.36M | 11.12M | 6.13M | 6.13M | 10.08M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 4.18M | 9.72M | 2.71M | 2.71M | 3.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 1.05M | 1.05M | 1.28M |
| Total Liabilities | 896.61K | 1.54M | 896.61K | 2.24M | 2.23M | 2.23M |
| Stockholders Equity | 10.23M | 2.82M | 10.23M | 3.89M | 7.84M | 8.88M |
Cash Flow | ||||||
| Free Cash Flow | -5.17M | -14.29M | -5.17M | -1.60M | -1.38M | -1.08M |
| Operating Cash Flow | -5.17M | -14.29M | -5.17M | -1.56M | -1.33M | -937.97K |
| Investing Cash Flow | -1.17M | -21.55K | -1.17M | -34.93K | -43.38K | -138.04K |
| Financing Cash Flow | 13.34M | 8.76M | 13.34M | 1.89M | 770.99K | 1.22M |
Pharmaust Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$68.35M | -5.28 | -62.49% | ― | ― | -13.64% | |
45 Neutral | AU$68.10M | -2.00 | -131.13% | ― | 2086.71% | -116.20% | |
43 Neutral | AU$84.07M | -1.51 | -265.55% | ― | -26.58% | -100.90% | |
42 Neutral | AU$49.25M | ― | -254.33% | ― | ― | 5.16% | |
42 Neutral | AU$86.95M | -3.40 | -69.20% | ― | ― | -73.11% | |
41 Neutral | AU$141.70M | -2.84 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:NUZ
Pharmaust Limited
0.07
-0.07
-51.82%
AU:PAR
Paradigm Biopharmaceuticals
0.16
-0.18
-52.94%
AU:IMM
Immutep Ltd
0.06
-0.24
-80.33%
AU:PTX
Prescient Therapeutics Limited
0.07
0.02
35.42%
AU:BOT
Botanix Pharmaceuticals Limited
0.03
-0.36
-93.42%
AU:RCE
Recce Pharmaceuticals Ltd.
0.49
0.20
68.97%
Pharmaust Limited Corporate Events
Neurizon Wins Ethics Approval for Phase 1 NUZ-001 Oral Liquid Study
May 12, 2026
Neurizon Therapeutics has secured ethics approval from the Bellberry Human Research Ethics Committee for a Phase 1 study of its NUZ-001 oral liquid formulation, marking a key milestone in the ALS drug’s development. The trial, which will enr...
Neurizon Therapeutics Discloses Director Departure and Remaining Equity Interests
May 12, 2026
Neurizon Therapeutics Limited has announced the cessation of Dr Michael Thurn as a director effective 8 May 2026, detailing his remaining interests in performance rights, unlisted options and fully paid ordinary shares. The disclosure clarifies Dr...
Neurizon Therapeutics appoints Dr Ross Murdoch as new director
May 12, 2026
Neurizon Therapeutics Limited has appointed Dr Ross Murdoch as a director effective 8 May 2026, according to an initial director’s interest notice lodged with the ASX. The filing indicates that Dr Murdoch currently holds no relevant interest...
Neurizon Targets Investor Visibility with NUZ-001 ALS Update at Microcap Conference
May 11, 2026
Neurizon Therapeutics will present at the 15th Annual Australian Microcap Investment Conference in Sydney, highlighting its clinical development efforts in neurodegenerative disease treatments. The company aims to raise its profile among Australia...
Neurizon steps up investor outreach with NUZ-001 ALS briefing series
Apr 30, 2026
Neurizon Therapeutics has launched a series of in-person investor briefings in Sydney and Perth, where Interim Executive Chairman Sergio Duchini will present recent corporate, clinical, and operational progress. The events will outline upcoming va...
Neurizon Therapeutics Seeks Quotation of 4.18 Million New Shares on ASX
Apr 30, 2026
Neurizon Therapeutics Limited has applied for quotation of 4,182,934 new ordinary fully paid shares on the ASX, with an issue date of 30 April 2026. The additional securities, arising from the exercise or conversion of existing options or other co...
Neurizon Advances NUZ-001 in HEALEY ALS Trial and Fortifies Balance Sheet
Apr 30, 2026
Neurizon Therapeutics reported a pivotal quarter marked by the first patient dosing and ongoing enrolment in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating its lead candidate NUZ-001 for ALS, alongside new preclinical data undersc...
Neurizon Clears 33.2m New Shares After Entitlement Offer Shortfall Placement
Apr 21, 2026
Neurizon Therapeutics has issued 33,212,500 fully paid ordinary shares at $0.08 per share to place the shortfall from its recent entitlement offer. The company states the shares were issued without a prospectus under the Corporations Act, confirms...
Neurizon Therapeutics Seeks ASX Quotation for 33.2 Million New Shares
Apr 20, 2026
Neurizon Therapeutics Limited has applied to the ASX for quotation of 33,212,500 new ordinary fully paid shares under the ticker NUZ. The securities were issued on 21 April 2026 as part of previously announced transactions, expanding the company&#...
Neurizon launches national investor briefings as ALS program enters key phase
Apr 16, 2026
Neurizon Therapeutics has launched a national investor engagement series, starting with in-person briefings in Sydney on 30 April 2026 and Perth on 4 May 2026, aimed at shareholders and prospective investors. Interim Executive Chairman Sergio Duch...
Neurizon Raises A$2.7m via Entitlement Offer Shortfall to Advance ALS Drug NUZ-001
Apr 15, 2026
Neurizon Therapeutics has secured firm commitments to raise about A$2.7 million via a placement of shortfall shares from its recent non-renounceable entitlement offer, lifting total proceeds from the offer to roughly A$8.5 million. The placement, ...
Neurizon issues shares for investor relations as it advances ALS-focused pipeline
Apr 1, 2026
Neurizon Therapeutics has issued 750,000 fully paid ordinary shares at a deemed price of $0.137 per share as part consideration for investor relations and strategic communications advisory services. The move modestly expands the company’s sh...
Neurizon Therapeutics Seeks ASX Quotation for 750,000 New Shares
Apr 1, 2026
Neurizon Therapeutics Limited has applied for quotation of 750,000 new ordinary fully paid shares on the Australian Securities Exchange, to be traded under its existing ticker NUZ. The new securities, issued on April 1, 2026, form part of a previo...
Neurizon preclinical data show NUZ-001 boosts dual protein-clearance pathways in ALS models
Apr 1, 2026
Neurizon Therapeutics has reported new preclinical data showing that its lead compound NUZ-001 and its sulfone metabolite enhance multiple protein clearance pathways in human neuronal models. The studies indicate increased activity in both autopha...
Neurizon Director Increases Stake Through $150,000 Share Placement
Mar 25, 2026
Neurizon Therapeutics has disclosed a change in director Sergio Duchini’s interests following his participation in a recent share placement. Through Kelbury Pty Ltd, where he is a director, Duchini acquired 1,875,000 fully paid ordinary shar...
Neurizon Sets April 2026 Expiry for NUZOA Listed Options
Mar 19, 2026
Neurizon Therapeutics has notified holders of its NUZOA listed options that these securities, each exercisable at $0.15 for one fully paid ordinary share, will expire at 5:00pm AEST on 30 April 2026. Official quotation of NUZOA on the ASX will cea...
Neurizon to Present NUZ-001 Science in HEALEY ALS Platform Trial Webinar
Mar 19, 2026
Neurizon Therapeutics will participate in a community webinar hosted by the Healey AMG Center for ALS, titled “HEALEY ALS Platform Trial Regimen I Science with Neurizon,” held on 19 March 2026 ET. The session will provide a high-level...
Neurizon Issues Director Shares, Affirms Compliance and Transparency
Mar 19, 2026
Neurizon Therapeutics has issued 9.5 million fully paid ordinary shares to its directors at $0.08 per share as part of their participation in the company’s December 2025 placement, a move previously approved by shareholders at a February 202...
Neurizon Therapeutics Seeks ASX Quotation for 9.5 Million New Shares
Mar 19, 2026
Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,500,000 new ordinary fully paid shares under the code NUZ, with an issue date of 19 March 2026. The application, lodged as an Appendix 2A, progresses the formal listing of the...
Neurizon CEO Michael Thurn Resigns as Biotech Launches Global Search for Successor
Mar 15, 2026
Neurizon Therapeutics has announced that Managing Director and Chief Executive Officer Dr Michael Thurn has resigned and will step down from his executive duties on 16 March 2026, remaining through his notice period until July to support an orderl...
Neurizon Expands NUZ-001 Huntington’s Disease Data at ASENT 2026
Mar 4, 2026
Neurizon Therapeutics has presented new preclinical data on its lead candidate NUZ-001 at the ASENT 2026 meeting, strengthening mechanistic support for its use in Huntington’s disease models. The data show that both NUZ-001 and its active me...
Neurizon Therapeutics Options Lapse, Trimming Potential Equity Overhang
Mar 3, 2026
Neurizon Therapeutics Limited has informed the market that 682,500 options with an exercise price of $0.10, expiring on 28 February 2026, have lapsed unexercised. The expiry of these options marginally reduces the company’s pool of potential...
Neurizon Draws First $5m Tranche to Advance ALS Drug Trial
Feb 27, 2026
Neurizon Therapeutics has drawn down the first $5 million tranche of its previously announced $20 million strategic convertible note facility with Obsidian Global GP, providing immediate funding support for its clinical programs. The financing und...
Neurizon Taps A$5m in Convertible Note Funding From Obsidian
Feb 27, 2026
Neurizon Therapeutics has issued a cleansing notice ahead of the expected issuance of 3,575,500 unquoted convertible notes to New York-based Obsidian Global GP under a two-year, up to A$20 million funding facility. The first A$5 million drawdown w...
Neurizon issues 10m shares under convertible note, affirms compliance and disclosure
Feb 27, 2026
Neurizon Therapeutics has issued 10,000,000 fully paid ordinary shares to Obsidian Global GP, LLC under a previously approved convertible note facility, following shareholder approval at a recent general meeting. The company confirmed the shares w...
Neurizon Begins Pivotal NUZ-001 Dosing in HEALEY ALS Platform Trial
Feb 25, 2026
Neurizon Therapeutics has begun dosing the first participant with its lead candidate NUZ-001 in Regimen I of the HEALEY ALS Platform Trial, a multicentre adaptive Phase 2/3 study run by the Sean M. Healey AMG Center for ALS at Mass General Brigha...
Neurizon Narrows Half-Year Loss as Other Income Jumps and Net Assets Strengthen
Feb 25, 2026
Neurizon Therapeutics Limited reported a sharply lower half-year loss for the period ended 31 December 2025, with the deficit narrowing 23.9% to $5.54 million as other income surged 241.5% to nearly $6.0 million. The company’s balance sheet ...
Neurizon Publishes General Meeting Results and Enhances Investor Engagement
Feb 20, 2026
Neurizon Therapeutics Limited has released the results of its general meeting, disclosing details of the resolutions considered and proxy votes received, as required under Australian corporate and listing rules. The company also directed investors...
Neurizon Therapeutics Issues Heavily Qualified General Meeting Presentation
Feb 20, 2026
Neurizon Therapeutics has released a general meeting presentation outlining information for shareholders while stressing that the material should not be regarded as financial, legal, tax or investment advice. The company emphasises that the presen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.